Assertio Therapeutics (ASRT) Misses Q1 EPS by 19c

Assertio Therapeutics (NASDAQ: ASRT) reported Q1 EPS of ($0.02), $0.19 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $15.6 million versus the consensus estimate of $37.51 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Centene names new CFO as Drew Asher plans to retire
• LeonaBio, Inc. (LONA) Tops Q2 EPS by 32c